2-thioxothiazolidin-4-one derivatives active as transthyretin ligands and uses thereof
Compounds of formula (II) are provided for stabilizing protein transthyretin (TTR) and inhibiting amyloid fibril formation, for example, transthyretin-mediated amyloid fibril formation, and for treating, preventing, or ameliorating one or more symptoms of amyloid diseases, for example, transthyretin-related amyloidosis (ATTR).
1. A compound of Formula (II):
or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, or prodrug thereof, wherein:
the double bond labeled with “a” is of (E)- or (Z)-configuration;
R 1 is —C(═O)OR a , —S(═O) 2 NHR a , —S(═O) 2 OR a , —P(═O)NH 2 (OR a ), —C(═O)N(R a ) 2 , —C(═O)NHOR a , —CHN 4 (tetrazolyl), or —OR a ;
R 2 is H or Halogen;
R 3 is H, —OH, Halogen, —CH 3 , or —OCH 3 ;
R 4 is H, —OR a , F, —OCH 3 , —NH 2 , —ONH 2 , —NCH 2 , —CN, or —SH;
R 5 is —OH, F, Cl, I, or —CH 3 ;
R 6 is H or Halogen;
each instance of R 7 is independently H, substituted or unsubstituted C 1-6 alkyl, —C(═O)OR a , or —C(═O)N(R a ) 2 ;
each instance of R a is independently H, substituted or unsubstituted acyl, substituted ethyl, substituted or unsubstituted, C 3-10 alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heteroaryl, a nitrogen protecting group when attached to a nitrogen atom, an oxygen protecting group when attached to an oxygen atom, or a sulfur protecting group when attached to a sulfur atom, or two instances of R a are joined to form a substituted or unsubstituted, heterocyclic ring, or substituted or unsubstituted, heteroaryl ring;
n is 1, 2, or 3; and
X is O.
2. The compound of claim 1 , wherein the compound is of the formula:
or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, or prodrug thereof, wherein
R 1 is —C(═O)OR a , —C(═O)N(R a ) 2 , —C(═O)NHOR a , or —OR a .
3. The compound of claim 1 , wherein the compound is of the formula:
or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, or prodrug thereof.
4. The compound of claim 1 , wherein the compound is of the formula:
or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, or prodrug thereof, wherein
R 1 is —C(═O)OR a , —C(═O)N(R a ) 2 , —C(═O)NHOR a , or —OR a .
5. The compound of claim 1 , wherein the compound is of the formula:
or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, or prodrug thereof.
6. The compound of claim 1 , wherein the compound is of the formula:
or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, or prodrug thereof, wherein
R 1 is —C(═O)OR a , —C(═O)N(R a ) 2 , —C(═O)NHOR a , or —OR a .
7. The compound of claim 1 , wherein the compound is of the formula:
or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, or prodrug thereof.
8. The compound of claim 1 , or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, or prodrug thereof, wherein the double bond labeled with “a” is of (Z)-configuration.
9. The compound of claim 1 , or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, or prodrug thereof, wherein R 1 is —C(═O)OR a .
10. The compound of claim 1 , wherein the compound is of the formula:
or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, or prodrug thereof.
11. A pharmaceutical preparation comprising the compound of claim 1 , or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, or prodrug thereof, and a pharmaceutically acceptable carrier.
12. A method of inhibiting amyloid fibril formation in a subject, the method comprising administering to a subject in need thereof the compound of claim 1 , or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, or prodrug thereof.
13. A method of treating an amyloid disease, the method comprising administering to a subject in need thereof the compound of claim 1 , or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, or prodrug thereof.
14. The method of claim 13 , wherein the amyloid disease is a transthyretin amyloid disease.
15. The method of claim 13 , wherein the amyloid disease is familial amyloid polyneuropathy.
16. The method of claim 13 , wherein the amyloid disease is familial amyloid cardiomyopathy.
17. The method of claim 13 , wherein the amyloid disease is senile systemic amyloidosis.
18. The compound of claim 1 , or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, or prodrug thereof, wherein R 1 is —OR a .
19. The compound of claim 1 , or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, or prodrug thereof, wherein R 4 is —OR a .
20. The compound of claim 1 , or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, or prodrug thereof, wherein R 4 is H.
21. The compound of claim 1 , or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, or prodrug thereof, wherein R 4 is —CN.
22. The compound of claim 1 , or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, or prodrug thereof, wherein each instance of R 7 is H.
23. The compound of claim 1 , or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, or prodrug thereof, wherein each instance of R a is H.
24. The compound of claim 1 , or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, or prodrug thereof, wherein n is 1.
25. The compound of claim 1 , or a pharmaceutically acceptable salt or tautomer thereof.
26. The pharmaceutical preparation of claim 11 comprising the compound of claim 1 , or a pharmaceutically acceptable salt or tautomer thereof, and a pharmaceutically acceptable carrier.
27. A method of treating macular degeneration, Stargardt's disease, or a related oculopathy, the method comprising administering to a subject in need thereof the compound of claim 1 , or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, or prodrug thereof.
28. The method of claim 27 of treating macular degeneration.
29. The method of claim 27 of treating Stargardt's disease.
30. The method of claim 12 comprising administering to the subject in need thereof the compound of claim 1 , or a pharmaceutically acceptable salt or tautomer thereof.
31. The method of claim 13 comprising administering to the subject in need thereof the compound of claim 1 , or a pharmaceutically acceptable salt or tautomer thereof.
32. The method of claim 27 comprising administering to the subject in need thereof the compound of claim 1 , or a pharmaceutically acceptable salt or tautomer thereof.
33. The method of claim 12 , wherein the subject is a human.
34. The method of claim 13 , wherein the subject is a human.
35. The method of claim 27 , wherein the subject is a human.